Compare TSEM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSEM | ILMN |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 26.7B |
| IPO Year | 1996 | 2000 |
| Metric | TSEM | ILMN |
|---|---|---|
| Price | $257.98 | $196.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 17 |
| Target Price | ★ $161.75 | $124.24 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $19.21 | $6.47 |
| Revenue Next Year | $26.62 | $5.58 |
| P/E Ratio | ★ $66.16 | $226.28 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.12 | $88.00 |
| 52 Week High | $319.94 | $199.14 |
| Indicator | TSEM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 63.79 |
| Support Level | $198.24 | $116.54 |
| Resistance Level | $278.73 | $196.66 |
| Average True Range (ATR) | 15.92 | 6.94 |
| MACD | 2.07 | -0.77 |
| Stochastic Oscillator | 67.24 | 92.41 |
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs) based on the design specifications of customers. The company's line of integrated circuits is incorporated into markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.